Novasep, a supplier of services and technologies for the life sciences industry, and McSAF, a French biotech specialized in bioconjugation tools to design bio drugs for health and diagnostics, have announced their successful collaboration for the preclinical production of ADCITMER, a next-generation ADC to treat neuroendocrine cancers.    Novasep performed a proof-of-concept study of McSAF’s bioconjugation technology through the production of the ADC at its bioconjugation unit at its Le Mans s...